Drawing for WCT

USPTO serial 75429517

WCT

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
—
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with WCT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

JAMES L BIKOFF

JAMES L BIKOFF ARTER & HADDEN LLP1801 K ST NW STE 400KWASHINGTON, DC 20006UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
035MANAGEMENT ASSISTANCE AND CONSULTATION FOR CLINICAL TRIALS OF INVESTIGATIONAL DRUGS, NAMELY, ARRANGING FOR SITES TO PERFORM CLINICAL TRIALS, ARRANGING FOR THE IMPORT, PACKAGING, SHIPPING, LABELING, AND DISTRIBUTION OF DRUGS AND OTHER INVESTIGATIONAL SUPPLIES TO AND FROM THE CLINICAL TRIAL SITES, ARRANGING FOR THE CENTRAL COLLECTION OF LABORATORY SPECIMENS FROM CLINICAL TRIAL SITES, MAKING ANY AND ALL FILINGS REQUIRED BY THE FOOD AND DRUG ADMINISTRATION FOR INVESTIGATIONAL NEW DRUGS, PREPARING STATISTICAL REPORTS RESULTING FROM CLINICAL TRIALSACTIVE—
037BUILDING INSPECTION, NAMELY, INSPECTING POTENTIAL SITES FOR HOSTING CLINICAL TRIALSACTIVE—
041TRAINING CLINICAL TRIAL SITE PERSONNEL CONCERNING DRUG PROTOCOL REQUIREMENTS AND THE USE OF TESTS AND RATING SYSTEMS FOR SUCH PROTOCOL; TRAINING CLINICAL TRIAL SITE PERSONNEL IN THE USE OF MEDICAL AND RESEARCH EQUIPMENT REQUIRED BY DRUG PROTOCOLSACTIVE—
042TECHNICAL WRITING OF CLINICAL REPORT FORMS WHICH ARE REQUIRED BY CLINICAL TRIAL DRUG PROTOCOLS; TECHNICAL WRITING OF CLINICAL TRIAL REPORTS; DATABASE DEVELOPMENT SERVICES TO PROCESS DATA COLLECTED FROM CLINICAL TRIALSACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ABN6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 20, 2000ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 1, 2000NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 9, 1999PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 8, 1999NPUBNOTICE OF PUBLICATION—
Jul 27, 1999CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 25, 1999CNSLLETTER OF SUSPENSION MAILED—
Apr 13, 1999CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 13, 1998CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 8, 1998DOCKASSIGNED TO EXAMINER—
Sep 22, 1998DOCKASSIGNED TO EXAMINER—
Sep 21, 1998DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance